摘要
［目的］探讨重组人粒细胞集落刺激因子对难治性或复发性急性淋巴细胞白血病患者联合化疗的疗效影响。［方法］将８４例病人随机分为治疗组和对照组各４２例。治疗组用米托蒽醌１０ｍｇ／ｍ２静滴，第１～３天，阿糖胞苷１００ｍｇ／ｍ２静滴，第１～５天，随后加用重组人粒细胞集落刺激因子７５μｇ或１５０μｇ。对照组米托蒽醌、阿糖胞苷用法相同，但不用重组人粒细胞集落刺激因子。［结果］治疗组与对照组相比，缩短了白细胞数恢复时间（１２天、２１天），降低了感染发生率（４６．３％、６９．１％），提高了ＣＲ率（５９．９％、３８．１％）。［结论］米托蒽醌、阿糖胞苷随后重组人粒细胞集落刺激因子治疗难治性、复发性急性淋巴细胞白血病，减轻了骨髓抑制程度，降低了感染发生率，显著提高了完全缓解率。
Purpose] To explore the effects of administration of filgrastim (G - CSF) on therapeutic effect of combination chemotherapy in acute lymphoblastic leukemia (ALL) patients. [Methods] Eighty - four cases of refractory or relapsed ALL were randomly divided into two groups: in the treatment group 42 patients were treated with chemotherapy regimen consisting of Mitoxantrone (MTZ, 10mg/m2 iv day 1 to 3) and Cytosine arabinoside (Ara - C, 100mg/m2 iv day 1 to 5) followed by intravenous administration of G - CSF (75 or 150μg). In the control group, 42 patients were treated with the same chemotherapy regimen without administration of G - CSF. [Results] The time of neutrophil recovery was significantly shorter in the treatment group (12 days), as compared with the control group (21 days), with decrease of incidence of severe infection from 69. 1 % in the control group to 46. 3% in treatment group. Complete remission rate from 38. 1 % in the control group increased to 59. 5 % in the treatment group. [Conclusion] The results indicate that administration of G - CSF following the treatment of refractory or relapsed ALL patients with regimen of MTZ and Ara - C reduces severity of myelosuppress and incidence of severe infection, and increase complete remission rate significantly.
